US FDA's Drug Breakthrough Bar May Be Set Too Low
This article was originally published in SRA
Executive Summary
If the Food and Drug Administration's Office of New Drugs director, John Jenkins, could start the breakthrough therapies program again, he probably would make it tougher for sponsors to gain the designation.